BR 8566 – 02/2009
Chapter 3 Evaluation of the efficacy and safety of RoACTEMRA ( tocilizumab): The first biologic to specifically inhibit the IL-6 receptor. BR 8566 – 02/2009. Content. RoACTEMRA - tocilizumab Preclinical evidence of IL-6 receptor inhibition Clinical trial data for tocilizumab
2.11k views • 173 slides